Dose recommendations for anticancer drugs in patients with renal or hepatic impairment

SD Krens, G Lassche, FGA Jansman… - The Lancet …, 2019 - thelancet.com
Renal or hepatic impairment is a common comorbidity for patients with cancer either
because of the disease itself, toxicity of previous anticancer treatments, or because of other …

[HTML][HTML] Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

V Nogales, WC Reinhold, S Varma… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Platinum-derived drugs such as cisplatin and carboplatin are among the most commonly
used cancer chemotherapy drugs, but very few specific molecular and cellular markers …

Applications and challenges in therapeutic drug monitoring of cancer treatment: A review

B Salman, M Al-Khabori - Journal of Oncology Pharmacy …, 2021 - journals.sagepub.com
Most anticancer agents show wide variability in pharmacokinetics (PK) and have a narrow
therapeutic index which makes fixed dosing suboptimal. To achieve the best therapeutic …

[HTML][HTML] Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy

H Abu-Sbeih, N Mallepally, R Goldstein, E Chen… - Journal of …, 2020 - ncbi.nlm.nih.gov
Background: Platinum-based therapy (PBT) can be limited by gastrointestinal adverse
events, particularly PBT-related colitis and diarrhea (PCD). We studied clinical features …

[HTML][HTML] Affinities to Oxaliplatin: Vitamins from B Group vs. Nucleobases

B Szefler, P Czeleń, K Wojtkowiak… - International Journal of …, 2022 - mdpi.com
Oxaliplatin, similar to Cisplatin, exhibits anticancer activity by interacting with DNA and
inducing programmed cell death. It is biotransformed through a number of spontaneous and …

[HTML][HTML] Differential cytotoxicity induced by the Titanium (IV) Salan complex Tc52 in G2-phase independent of DNA damage

T Pesch, H Schuhwerk, P Wyrsch, T Immel, W Dirks… - BMC cancer, 2016 - Springer
Background Chemotherapy is one of the major treatment modalities for cancer. Metal-based
compounds such as derivatives of cisplatin are in the front line of therapy against a subset of …

Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors

J Aguiar Zdovc, M Vaupotič, G Marolt, L Knez… - Cancer chemotherapy …, 2022 - Springer
Purpose Cisplatin-etoposide treatment is recommended as a first line in small cell lung
cancer patients (SCLC). However, the prognosis is poor and the dosing is not tailored …

Early neuropathy related to oxaliplatin treatment in advanced and recurrent colorectal cancer

T Nagata, KI Fukuda, M Tamai, A Taniguchi… - Anticancer …, 2019 - ar.iiarjournals.org
Background/Aim: Chemotherapy dose adjustments in colorectal cancer are usually based
on body surface area (BSA). The goal of this study was to investigate patients with nutritional …

Biochemical study in Ehrlich carcinoma cells-bearing mice treated with arsenic trioxide and cisplatin

WMM Ibrahim, SM Foad - Advances in Environmental and Life …, 2022 - journals.ekb.eg
The purpose of the study was to evaluate the effect of arsenic trioxide and cisplatin on
Ehrlich ascites carcinoma (EAC) bearing mice. Fifty female Albino mice were separated into …

Assessment of Autophagy as Possible Mechanism of the Antitumor Effects of Arsenic Trioxide and/or Cisplatin on Ehrlich Ascites Carcinoma Model.

MA Mansour, AF Salama… - Alexandria Journal …, 2019 - openresearch.lsbu.ac.uk
Arsenic trioxide (As2O3)(ATO) and cisplatin (CIS) have potent antineoplastic effects in
several types of cancer. Autophagy is important for normal cell function and survival, it is …